| Purpose:To explore the effects of Urinary Kallidinogenase on the level of serum oxidized low density lipoprotein(ox-LDL), interleukin-1(IL-1) and vascular endothelial growth factor(VEGF) in patients with acute cerebral infarction, and to explore Urinary Kallidinogenase can play roles in physiological and pathological processes of infarction throughout suppressing the plurality of oxidation, anti-inflammatory and angiogenic regeneration.Method:Selected 66 cases of cerebral infarction onset time in one week, divided into test group(33 cases) and control group(33 cases). The experimental group contains 17 males and 16 females, with an average of(65.6 ± 1.2) years old; the control group contains 18 males and 15 females, with an average of(65.2 ± 1.7) years old. There was not statistically significant between the two groups of patients in age and the treatment of time. The experimental group received Urinary Kallidinogenase(Kai Li Kang, Techpool Biochemical Pharmaceutical Company) 0.15 PNA with 0.9% saline 100 ml, 1 / day, intravenous, added in traditional Chinese medicine, adjust blood pressure, regulate blood sugar,adjust blood lipids and other treatment, with an average of 14 th days’ treatment. The control group received Kudiezi(Diemailing, Tonghua China Pharmaceutical Co., Ltd.) 40 ml with 250 ml of 0.9% saline, 1 / day, intravenous, while the addition of drugs to improve circulation, adjust blood pressure, regulate blood sugar, cholesterol and other adjustments treatment, with an average of 14 th days’ treatment. Two groups of patients were taken fasting cubital venous blood 2m L within 24 hours after admission and after the end of treatment, and get the serum specimens from blood by centrifugation(4000r / min, 3min). Placed the serum specimens in-80 ℃ refrigerator. Experimental samples were determined by Double-antibody sandwich enzyme-linked by immunosorbent assay(ELISA), the kit was produced by Shenzhen Jingmei company.Result:The experimental group levels of serum ox-LDL, IL-1, VEGF before treatment were(136.5 ± 44.3) μg/L,(109.6 ± 34.8) ng/L,(970.8 ± 243.7) ng/L, the control group levels of serum ox-LDL, IL-1, VEGF before treatment were(137.7 ± 41.8) μg/L,(107.3 ± 29.4) ng/L,(980.0 ± 290.7) ng/L. After treatment, the experimental group levels of serum ox-LDL, IL-1, VEGF were(112.1 ± 33.3) μg/L,(90.5 ± 29.3) ng/L,(1150.0 ± 240.6) ng/L, the control group levels of serum ox-LDL, IL-1, VEGF were(130.0 ± 37.9) μg/L,(105.5 ± 30.5) ng/L,(1012.7 ± 303.3) ng/L. The results of the experimental data statistics: There were no statistically significant between the experimental group and the control group in serum levels of ox-LDL, IL-1, VEGF before treatment. Compared with before treatment, the detected factors were changed significantly after treatment and the difference wes statistically significant(p <0.05), and the experimental group was changed more significantly than the control group(p<0.05). Analysis result shows that Urinary Kallidinogenase is better able to reduce the levels of serm ox-LDL, IL-1, and improve serum VEGF levels in patients with cerebral infarction.Conclusion:1. The Urinary Kallidinogenase can reduce the level of serum ox-LDL,IL-1 in acute cerebral infarction patients effectively, thus confirming it has the effects of antioxidant, anti-inflammatory pharmacological.2. The Urinary Kallidinogenase can effectively improve the level of serum VEGF in acute cerebral infarction patients, thus confirming it has the fuction of.3. The Urinary Kallidinogenase can play a role in the treatment of acute cerebral infarction with multiple links, it has practice to be popularized in clinical as a new drug with multi-target for the treatment. |
PDF Full Text Request